調査・レポート
2026年9月14日•1分で読めます
Il Dong Biosciences Publishes Probiotic IDCC 1201 Trial Results in Nutrients Journal
Il Dong Biosciences reported that its probiotic strain IDCC 1201 improved gut symptoms and quality of life in adults with functional bowel disorders, results published in Nutrients.
調査・レポート
2026年9月13日•1分で読めます
Il Dong BioScience Publishes IDCC 1201 Gut Health Study in Nutrients
Il Dong BioScience announced that its probiotic strain IDCC 1201 reduced abdominal bloating and altered gut microbiota in a clinical trial, with results published in the journal Nutrients.
2
調査・レポート
2026年9月13日•1分で読めます
BioNTech/Genentech Personalized mRNA Cancer Vaccine Phase 2 Halted Over Safety Concerns
Phase 2 of BioNTech and Genentech's personalized mRNA colorectal cancer vaccine BNT122 was stopped early after higher deaths in the vaccine arm.
調査・レポート
2026年9月8日•1分で読めます
Robot-Assisted Knee Replacement Shows No Long-Term Benefit Over Conventional Surgery, Study Finds
A UK randomized trial of 339 patients found robot-assisted knee arthroplasty improves surgical precision but offers no significant advantage in pain, function, or recovery after one year.
調査・レポート
2026年9月4日•1分で読めます
First Bundibugyo Ebola Virus Vaccine Enters Phase 1 Trial in UK
A ChAdOx1 BDBV vaccine targeting the Bundibugyo Ebola virus begins a Phase 1 safety and immunogenicity study in 50 healthy UK adults aged 18‑55.
調査・レポート
2026年9月4日•1分で読めます
Progen and Rani Therapeutics Report Early Phase 1a Results for Oral GLP‑1/GLP‑2 Obesity Drug RPG‑102
The co‑developed oral GLP‑1/GLP‑2 dual‑action obesity candidate RPG‑102 showed higher drug exposure and comparable durability versus subcutaneous injection in early Phase 1a data.
調査・レポート
2026年9月2日•1分で読めます
STP0404 HIV‑1 Candidate Shows Significant Antiviral Activity in US Phase 2a Trial
STP0404, an HIV‑1 treatment candidate from ST Pharm, demonstrated significant antiviral effects across all dose groups in a US Phase 2a study, prompting optimism for further development.
調査・レポート
2026年9月1日•1分で読めます
Ipsen's Dysport Meets Primary Endpoints in Phase 3 Trials for Episodic and Chronic Migraine Prevention
Ipsen reported that its botulinum toxin Dysport achieved primary goals in two Phase 3 studies for preventing episodic and chronic migraine, marking the first positive result in episodic migraine for a botulinum product.
調査・レポート
2026年9月1日•1分で読めます
Satellos Bioscience Reports Activity Signal for DMD Candidate SAT-3247 in Adult Study
Satellos Bioscience observed a drug activity signal for its oral AAK1‑targeting candidate SAT‑3247 in a Phase 1a/b trial of four adult Duchenne muscular dystrophy patients.
調査・レポート
2026年8月31日•1分で読めます
Keenova Therapeutics' Xiaflex Meets Primary Endpoint in Phase 3 Plantar Fibromatosis Trial
Xiaflex, the injectable enzyme already approved for Dupuytren's contracture and Peyronie's disease, achieved the primary endpoint in a phase 3 study of 436 plantar fibromatosis patients, opening a potential third indication.
調査・レポート
2026年8月31日•1分で読めます
Hanmi Pharm Pushes Belvarafenib into Phase 2 for NRAS‑Mutant Melanoma
Hanmi Pharm is developing Belvarafenib, the first oral targeted therapy for NRAS‑mutant melanoma, now in Phase 2 with a goal of conditional approval by 2028.
調査・レポート
2026年8月31日•1分で読めます
Novartis Korea shares long-term PNH drug data at EHA 2026
Novartis Korea presented up to 6‑year follow‑up results and real‑world data for its PNH therapy iptacopan (PAVALTA) at the EHA 2026 meeting in Milan.